Going Mobile - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Going Mobile
Seven Reasons Why Pharmaceutical Makers Are Adopting Mobile Technology


Pharmaceutical Technology


When companies end their dependence on paperwork, they typically experience productivity increases of 10–25% (2). They also see an improvement in first-time fix rates because their skill teams have more data at the point of performance. The labor savings and increase in productivity easily offset the initial investment costs.

Deploying multiple mobile products that use a single platform technology decreases application costs and results in exponential increases in data for better management.

Conclusion

In the pharmaceutical industry, the adoption of mobile technology is an ongoing trend. Organizations are adopting mobile technology to remain competitive. The seven reasons why mobile technology is taking off in the pharmaceutical industry are straightforward and time-tested. New uses for the technology continue to emerge as operational and organizational experts are exposed to the software and users see its convenience.

Richard W. Padula is president and chief executive officer of Syclo, 1721 Moon Lake Blvd., Suite 300, Hoffman Estates, IL 60169, tel. 847.230.3800,
http://www.syclo.com/.

References

1. C. Garritty and K. El Emam, "Who's Using PDAs? Estimates of PDA Use by Health Care Providers: A Systematic Review of Surveys," J. Med. Internet Res. 8 (2), e7 (2006).

2. Syclo, "Syclo Mobile Results Customer Survey" (Syclo, Hoffman Estates, IL, 2004).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here